Featured Research

from universities, journals, and other organizations

Potential drug compound attacks Parkinson's on two fronts

Date:
June 20, 2013
Source:
Scripps Research Institute
Summary:
Scientists have found a compound that could counter Parkinson’s disease in two ways at once. Scientists now describe a “dual inhibitor” that attacks a pair of proteins closely associated with development of Parkinson’s disease.

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have found a compound that could counter Parkinson's disease in two ways at once.

Related Articles


In a new study published recently online ahead of print by the journal ACS Chemical Biology, the scientists describe a "dual inhibitor" -- two compounds in a single molecule -- that attacks a pair of proteins closely associated with development of Parkinson's disease.

"In general, these two enzymes amplify the effect of each other," said team leader Phil LoGrasso, a TSRI professor who has been a pioneer in the development of JNK inhibitors for the treatment of neurodegenerative diseases. "What we were looking for is a high-affinity, high-selectivity treatment that is additive or synergistic in its effect -- a one-two punch."

That could be what they found.

This new dual inhibitor attacks two enzymes -- the leucine-rich repeat kinase 2 (LRRK2) and the c-jun-N-terminal kinase (JNK) -- pronounced "junk." Genetic testing of several thousand Parkinson's patients has shown that mutations in the LRRK2 gene increase the risk of Parkinson's disease, while JNK has been shown to play an important role in neuron (nerve cell) survival in a range of neurodegenerative diseases. As such, they have become highly viable targets for drugs to treat disorders such as Parkinson's disease.

A dual inhibitor ultimately would be preferred over separate individual JNK and LRRK2 inhibitors because a combination molecule would eliminate complications of drug-drug interactions and the need to optimize individual inhibitor doses for efficacy, the study noted.

Now the team's new dual inhibitor will need to be optimized for potency, high selectivity (which reduces off-target side effects) and bioavailability so it can be tested in animal models of Parkinson's disease.


Story Source:

The above story is based on materials provided by Scripps Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Yangbo Feng, Jeremy W. Chambers, Sarah Iqbal, Marcel Koenig, HaJeung Park, Lisa Cherry, Pamela Hernandez, Mariana Figuera-Losada, Philip V. LoGrasso. A Small Molecule Bidentate-Binding Dual Inhibitor Probe of the LRRK2 and JNK Kinases. ACS Chemical Biology, 2013; 130610145315006 DOI: 10.1021/cb3006165

Cite This Page:

Scripps Research Institute. "Potential drug compound attacks Parkinson's on two fronts." ScienceDaily. ScienceDaily, 20 June 2013. <www.sciencedaily.com/releases/2013/06/130620111138.htm>.
Scripps Research Institute. (2013, June 20). Potential drug compound attacks Parkinson's on two fronts. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2013/06/130620111138.htm
Scripps Research Institute. "Potential drug compound attacks Parkinson's on two fronts." ScienceDaily. www.sciencedaily.com/releases/2013/06/130620111138.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Suicide Rates Up For Young Women In U.S.

Suicide Rates Up For Young Women In U.S.

Newsy (Mar. 6, 2015) According to a report from the CDC, suicide rates among young women increased from 1994 to 2012 while rates among young men have decreased. Video provided by Newsy
Powered by NewsLook.com
Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Liberia Releases Last Ebola Patient, But Threat Remains

Liberia Releases Last Ebola Patient, But Threat Remains

Newsy (Mar. 5, 2015) Liberia&apos;s last Ebola patient has been released, and the country hasn&apos;t recorded a new case in a week. However, fears of another outbreak still exist. Video provided by Newsy
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins